Follow us on Twitter
twitter icon@FreshPatents

Factor patents

      

This page is updated frequently with new Factor-related patent applications.




 Method and system for crest factor reduction patent thumbnailnew patent Method and system for crest factor reduction
Methods and systems for crest factor reduction may comprise generating an original waveform to be amplified by a programmable gain amplifier (pga); generating a distortion signal utilizing a pga model that predicts an output signal of the pga based on the original waveform; generating an error signal by subtracting out the original waveform from the distortion signal; filtering the generated error signal; generating a conditioned waveform with crest factor reduced from that of the original waveform by adding the filtered error signal to the original waveform; and amplifying the conditioned waveform. The crest factor of the original waveform may be reduced based on spectral mask requirements.
Maxlinear, Inc.


 High efficiency antenna patent thumbnailnew patent High efficiency antenna
Antenna designs are disclosed that exhibit both high bandwidth and efficiency. A first aspect of the invention concerns the form factor of the antenna; a second aspect of the invention concerns the ease with which the antenna is manufactured; and a third aspect concerns the superior performance exhibits by the antenna across a large bandwidth..
Netgear, Inc.


 Multimode image and spectral reader patent thumbnailnew patent Multimode image and spectral reader
A multi-mode reader instrument capable of detecting and determining digital data from a signal from one or more markers, indicia or taggants on an object, the markers, indicia or taggants such as a bar code, a qr code, an rfid, an optical compound, a fluorescent compound, a phosphorescent compound, a dna taggant, an upconverting phosphor (ucp), a chemical dye, a digitized image, a radioactive compound, an olfactory compound or a thermal attribute of the object is provided. Also, provided is a method and a system for identifying an object, the system includes: a multi-mode reader instrument for detecting data from a signal from one or more markers, indicia or taggants on an object and assignment of digital code for the marker and a database for securing and retrieving information relevant to the item..
Apdn (b.v.i.), Inc.


 Methods of identifying subjects responsive to treatment for an autoimmune disease and compositions for treating the same patent thumbnailnew patent Methods of identifying subjects responsive to treatment for an autoimmune disease and compositions for treating the same
Methods of identifying a subject having an autoimmune disease, such as type 1 diabetes, as likely to respond to treatment with a tumor necrosis factor-alpha (tnf-α) receptor ii activator, involving measuring cd8 protein density on the surface of autoreactive cd8+ t cells and identifying the subject as likely to respond to the treatment if the cd8 protein density is reduced relative to a reference cd8+ t cell. For type 1 diabetes, the method may involve measuring c-peptide levels in an in vitro biological sample from the subject, identifying the subject as likely to respond to the treatment if the c-peptide levels are detectable, and identifying the subject as unlikely to respond to the treatment if the c-peptide levels are substantially undetectable.
The General Hospital Corporation


 Led lamp patent thumbnailnew patent Led lamp
The led lamp has a relatively long, narrow configuration similar to that of cfl bulbs. Because the lamp operates at relatively high power and produces significant lumens, a significant amount of heat is generated by the led assembly.
Cree, Inc.


 Heat release rate waveform calculation apparatus and heat release rate waveform calculation  internal combustion engine patent thumbnailnew patent Heat release rate waveform calculation apparatus and heat release rate waveform calculation internal combustion engine
A period from ignition timing to maximum heat release rate timing, at which a heat release rate is maximum, within a combustion period of air-fuel mixture is defined as a first combustion period that is one of characteristic values of a heat release rate waveform. The first combustion period is estimated based on a cylinder volume at the maximum heat release rate timing (maximum heat release rate cylinder volume) irrespective of any of an engine load factor, an egr rate, an air-fuel ratio, an oil or coolant temperature and opening and closing timing of an exhaust valve through correction by the use of the exponential function of an engine rotation speed with an exponent of a value commensurate with a tumble ratio.
Toyota Jidosha Kabushiki Kaisha


 Select fire switch form factor system and method patent thumbnailnew patent Select fire switch form factor system and method
A wellbore select fire switch retaining member system and method with an integrated through wire and ground wire in a switch sub. The system/method includes a retaining member that has a form factor acceptable by a conventional switch sub.
Geodynamics, Inc.


 Methods and kits for diagnosing, prognosing and monitoring parkinson's disease patent thumbnailnew patent Methods and kits for diagnosing, prognosing and monitoring parkinson's disease
Network-based meta-analysis of four independent microarray studies identified the hepatocyte nuclear factor (hnf4a), a transcription factor associated with gluconeogenesis and diabetes, as a central regulatory hub gene upregulated in blood of pd patients. In parallel, the polypyrimidine tract binding protein 1 (ptbp1), involved in the stabilization and mrna translation of insulin, was identified as the most downregulated gene.
Rosalind Franklin University Of Medicine And Science


 Vector comprising specific promoter and gene encoding specific protein, transgenic plant into which the vector has been introduced, and  improving polyisoprenoid production by introducing the vector into plant patent thumbnailnew patent Vector comprising specific promoter and gene encoding specific protein, transgenic plant into which the vector has been introduced, and improving polyisoprenoid production by introducing the vector into plant
Provided is a vector capable of improving polyisoprenoid production through the introduction of the vector into a plant using gene recombination techniques. A vector comprising: a promoter of a gene encoding myc1 transcription factor; and a gene encoding a protein involved in polyisoprenoid biosynthesis, the gene being functionally linked to the promoter..
Sumitomo Rubber Industries, Ltd.


 Method for mobilizing stem and/or progenitor cells patent thumbnailnew patent Method for mobilizing stem and/or progenitor cells
The present disclosure relates to a method for treatment or prevention of diseases have an increased level of insulin-like growth factor i (igf-i). The method comprises administration of a growth hormone (gh) variant having antagonistic activity in combination with an oligonucleotide targeted to growth hormone receptor (ghr) to a subject in need..
Antisense Therapeutics Ltd


new patent

Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same


Methods of isolating highly sialylated recombinant vitamin k dependent proteins, particularly factor ix, by chromatographic methods are described. The highly sialylated recombinant proteins are characterized.
Cnj Holdings, Inc.


new patent

Cell culture processes


Culturing heterologous protein-secreting mammalian cells, such as cho or bhk cells, at 35.1-36.5° c. And/or at ph 7.15-7.20 and/or at a dissolved co2 concentration of 10% or lower.
Baxalta Gmbh


new patent

Vegf antagonist formulations suitable for intravitreal administration


Ophthalmic formulations of a vascular endothelial growth factor (vegf)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation.
Regeneron Pharmaceuticals, Inc.


new patent

Vegf antagonist formulations


Formulations of a vascular endothelial growth factor (vegf)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of seq id no:4..
Regeneron Pharmaceuticals, Inc.


new patent

Novel epitope for switching to th17 cell and use thereof


The present invention relates to a novel epitope to convert t cell to type 17 helper t (th17) cell. Specifically, the present invention relates to an epitope constituting the 41st to 50th amino acids (seq id no.
National Cancer Center


new patent

Pyridine derivative and medical use thereof


The present invention relates to the field of pharmaceutical chemistry, specifically to a class of compounds containing lactam and derivative thereof, and especially to a pyridine derivative as shown in general formula (i), preparation method and the use thereof as a factor xa inhibitor. The present invention further relates to the medical use of the compound and derivative thereof in preparation of anticoagulant drugs, particularly to the use in preparation of drugs for preventing or treating thrombosis or embolism..
Chengdu Easton Biopharmaceutical Co., Ltd.


new patent

Fast curing porous materials and control thereof


High internal phase emulsions (hipes) and polyhipes formed therefrom. Hipe components have been adjusted to delay and/or prevent polymerization and free radical decomposition at certain temperatures.
The Texas A & M University System


new patent

Artificial transcription factors comprising a sliding domain and uses thereof


The present invention relates to compositions which may comprise a non-naturally occurring or engineered artificial transcription factor, wherein the transcription factor may comprise a sequence specific dna binding domain, a sliding domain, and one or more linkers, wherein the dna binding domain and the sliding domain are operably connected by the one or more linkers, and uses thereof. Methods involving the use of a non-naturally occurring or engineered artificial transcription factors and pharmaceutical compositions, methods for treating cancer, a degenerative disease, a genetic disease or an infectious disease as well as diagnostic methods are also contemplated by the present invention..
Massachusetts Institute Of Technology


new patent

Factor ix polypeptides and methods of use thereof


The present invention provides methods of administering factor ix; methods of administering chimeric and hybrid polypeptides comprising factor ix; chimeric and hybrid polypeptides comprising factor ix; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.. .
Biogen Hemophilia Inc.


new patent

Medicament for treating olfaction disorder


The object of the present invention is achieved by an olfactory disturbance therapeutic agent including at least one active ingredient that is selected from among a group consisting of insulin, insulin analogs, and insulin secretagogues. Preferably, the olfactory disturbance therapeutic agent is used for people with olfactory disturbance who have, or are at risk of having, impaired insulin secretion or insulin resistance, or for people who could suffer an iatrogenic increase in blood sugar level or a disturbance in a balance of adrenocortical hormone stemming from a long-term use of steroid as olfactory disturbance treatment..

new patent

Compositions and methods for mesenchymal/stromal stem cell rejuvenation and tissue repair by enhanced co-expression of telomerase and myocardin


A major risk factor for ischemic heart disease is advanced age. In adult bone marrow and other tissues, the number and function of stem cells decline with aging.

new patent

Tissue integration design for seamless implant fixation


The present invention relates to orthopaedic implants having a fenestrated hollow shell and a biologic core. These design features provide an improved interface between the implant and the surrounding tissue aiding fixation, and provide a vehicle for applying new bone healing and enhancing modalities, such as gene therapy, tissue engineering, and growth factors..
Biedermann Technologies Gmbh & Co. Kg


new patent

Cylinder pan chiller


A glycol pan chiller is configured in a unique cylinder form factor that achieves new efficiencies in power savings and cooling. A new cylindrical cooling assembly comprises three concentrically disposed cylinders attached together at their respective top ends to create an upper lip area 219 or shelf area that provides top end insulation and a useful shelf area.

Linear led illumination device with improved color mixing


A linear multi-color led illumination device that produces uniform color throughout the output light beam without the use of excessively large optics or optical losses is disclosed herein. Embodiments for improving color mixing in the linear illumination device include, but are not limited to, a shallow dome encapsulating a plurality of emission leds within an emitter module, a unique arrangement of a plurality of such emitter modules in a linear light form factor, and special reflectors designed to improve color mixing between the plurality of emitter modules.
Ketra, Inc.


Method and determining shapes for devices based on privacy policy


An approach is provided for determining at least one interaction mode of at least one application executing on at least one device, wherein the at least one device supports shifting from among a plurality of physical form factors. The approach also involves determining at least one selected physical form factor from among the plurality of physical form factors based, at least in part, on the at least one interaction mode, at least one user privacy policy, or a combination thereof.
Nokia Technologies Oy


Genetic testing for improved cattle fertility


Arrays of nucleic acid molecules, kits, methods of genotyping and marker assisted bovine breeding methods based on novel snps on genes of the bovine transforming growth factor-β (tgf-β) signaling pathway for improved bovine fertilization rate. The methods and compositions of the present invention are related to snps in the dna-binding protein inhibitor 3 (id3) gene, and in the bone morphogenetic protein 4 (bmp4) gene corresponding to position 2702 of seq id no: 2.
Wisconsin Alumni Research Foundation


Lyophilized formulations for factor xa antidote


The present disclosure relates to solutions and methods of preparing lyophilized formulations of factor xa (fxa) antidotes. A suitable aqueous formulation suitable for lyophilization can include a fxa antidote, a solubilizing agent, a stabilizer, and a crystalline component, wherein the formulation does not collapse during lyophilization..
Portola Pharmaceuticals, Inc.


Renal progenitor cells


A method is provided for simultaneously producing both nephron progenitor cells and ureteric epithelial progenitor cells including the step of contacting intermediate mesoderm cells with: fibroblast growth factor (9) and/or fibroblast growth factor (20) and optionally, one or more selected from the group consisting of. Bone morphogenic protein 7; heparin: a wnt agonist; retinoic acid; and an ra antagonist.
The University Of Queensland


Methods and compositions for ex vivo generation of developmentally competent eggs from germ line cells using autologous cell systems


The present technology provides for methods for the directed differentiation of multi-potent cells, female germ line stem cells, or oogonial stem cells into oocytes, granulosa cells and/or granulosa precursor cells, i.e.,“synthetic granulosa cells.” the synthetic granulosa cells are useful in methods for growth and maturation of follicles or follicle-like structures and immature oocytes. Additionally, the synthetic granulosa cells are useful in methods of increasing ovarian derived hormones and growth factors in a subject in need thereof..
Northeastern University


In vitro production of foregut stem cells


This invention relates to the differentiation of pluripotent cells (pscs) into foregut stem cells (fscs) using a definitive endoderm induction medium comprising a tgffi ligand, fibroblast growth factor (fgf), bone morphogenetic protein (bmp) and a pi3k inhibitor to differentiate the pluripotent cells into definitive endoderm cells and a foregut induction medium comprising a tgfβ ligand to differentiate the definitive endoderm cells into foregut stem cells (fscs). Methods of differentiation, populations of foregut stem cells, culture media and kits are provided..
Cambridge Enterprise Limited


Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors


This invention provides antibodies that interact with or bind to human nerve growth factor (ngf) and neutralize the function of ngf thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing ngf function, and particularly for treating ngf-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-ngf antibodies.
E.r. Squibb & Sons, L.l.c.


Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use


The present disclosure provides chimeric proteins having an n-terminus coupled to a c-terminus, wherein the n-terminus comprises an n-terminal portion of fibroblast growth factor (fgf) 2 and the c-terminus comprises a portion of an fgf1 protein. Such fgf2/fgf1 chimeras can further include a fibroblast growth factor receptor (fgfr) 1c-binding protein, a β-klotho-binding protein, or both.
Salk Institute For Biological Studies


Proteins with diagnostic and therapeutic uses


The present invention provides a recombinant protein capable of binding to complement factor h (cfh), and thereby inducing increased binding of c3d and c3b by bound cfh compared to unbound cfh. Methods and medical devices for using utilising the same are also described..
The University Court Of The University Of Edinburg


Fgf modulation of in vivo antibody production and humoral immunity


The invention provides methods for increasing or decreasing antibody production in vivo by inhibiting or promoting the activity of fibroblast growth factor-2 (fgf2) respectively.. .

Compositions and methods for increasing the half-life of factor xa


Compositions and methods for the modulation of hemostasis are disclosed.. .
The Children's Hospital Philadelphia


Enterprise data processing architecture with distributed intelligence


The architecture design and functional operation of an enterprise data processing system with distributed intelligence capable of monitoring sensor networked systems and processing large sets of data as required by the application is disclosed in this invention. The system is based on smart sensor/actuator nodes, local processing units, a server, and clients.

Subscriber-based system for custom evaluations of business relationship risk


A server generates a risk tier map based on risk inventory data for a subscriber. The risk tier map comprises a plurality of risk tiers.

Extracting and recommending business processes from evidence in natural language systems


A natural language question and answer system analyzes a question to determine key characteristics (such as focus and lexical answer type), and matches those characteristics to business processes from business process repositories. The matching business processes are ranked and at least one is presented as a recommended answer to the user.
International Business Machines Corporation


Folded telephoto camera lens system


A folded telephoto lens system may include multiple lenses with refractive power and a light path folding element. Light entering the camera through lens(es) on a first path is refracted to the folding element, which changes direction of the light on to a second path with lens(es) that refract the light to form an image plane at a photosensor.
Apple Inc.


Method of detection of platelet-activating antibodies that cause heparin-induced thrombocytopenia/thrombosis


The present invention provides a method of detecting platelet activation in a patient, the method comprising the steps of a) obtaining a blood sample from a patient suspected of having heparin-induced thrombo-cytopenia (hit); b) incubating an effective amount of platelet factor 4 (pf4) with a sample of platelets to yield a sample of pf4-treated platelets; c) contacting the patient blood sample with the pf4-treated platelets; and d) measuring the extent of platelet activation, wherein an increase in platelet activation compared with results obtained using a normal blood sample is indicative of the patient having hit.. .
Blood Center Research Foundation


Methods and kits for determining von willebrand factor activity in the absence of ristocetin


Described herein are method(s), kit(s), reagent(s) and the like for determining von willebrand factor (vwf) activity in a sample in the absence of ristocetin.. .
Siemens Healthcare Diagnostics Products Gmbh


Process for preparing a colour chart


The invention relates to a process for arranging a plurality of colours or coloured objects in a defined sequence so that each colour or coloured object has at least one neighbouring colour or coloured object, comprising the steps of a) assigning all colours or coloured objects a position in an at least two-dimensional colour space, b) assigning all neighbouring colours or coloured objects a colour difference value corresponding to the length of a vector connecting the neighbouring colours in the colour space, c) assigning a direction to every vector in the colour space connecting two neighbouring colours or coloured objects, d) arranging the sequence of colours or coloured objects in such a way that the overall sum of i. All colour difference values over the sequence and ii.
Akzo Nobel Coatings International B.v.


Method and reprogramming living cells


A method and an apparatus for reprogramming living cells without using viruses. In that method a cocktail comprising at least two transcription factors and a microrna is transfected into the interior of at least one cell in order to convert this cell into ips cells or into another type of cell, by storing the cells to be converted in an aqueous environment of the cocktail without viral carriers and focusing a femtosecond laser in a laser scanning microscope with a numerical aperture between 0.9 and 1.5 on a cell membrane of the cell to be reprogrammed and controlling the position of the focus.
Jenlab Gmbh


Aspergillus mutant strain and transformant thereof


Provided are an aspergillus mutant strain which can dramatically enhance production of a heterologous enzyme when a saccharifying enzyme gene is transferred into the strain to perform transformation and a transformant having a saccharifying enzyme gene transferred into the aspergillus mutant strain. The aspergillus mutant strain has been completely or partially deficient in three genes of aspergillus oryzae strain ho2 (accession number: nite bp-01750): a prtr gene coding for a transcription factor; a pepa gene coding for an extracellular acid protease; and a cpi gene coding for an extracellular acid carboxypeptidase..
Honda Motor Co., Ltd.


Optimized human clotting factor viii gene expression cassettes and their use


The invention relates to synthetic liver-specific promoters and expression constructs for producing polypeptides and functional nucleic acids in the liver of a subject. The invention further relates to factor viii proteins containing modifications in the amino acid sequence of the factor viii protein, as well as nucleic acid constructs encoding the factor viii proteins and methods of using these compositions to treat a bleeding disorder..
The University Of North Carolina At Chapel Hill


Trka kinase inhibitors, compositions and methods thereof


The present invention is directed to benzyl urea compounds of formula (i) which are tropomyosin-related kinase (trk) family protein kinase inhibitors, and hence may be useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (ngf) receptor trk-a, trk-b and/or trk-c.. .
Merck Sharp & Dohme Corp.


Quinolone derivatives as fibroblast growth factor receptor inhibitors


Compounds that are fibroblast growth factor inhibitors (fgfr) and are therefore useful for the treatment of diseases treatable by inhibition of fgfr are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds..
Principia Biopharma, Inc.


Factor xia inhibitors


And pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective factor xia inhibitors or dual inhibitors of factor xia and plasma kallikrein..

Trka kinase inhibitors, compositions and methods thereof


The present invention is directed to benzyl urea compounds of formula (i) which are tropomyosin-related kinase (trk) family protein kinase inhibitors, and hence may be useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (ngf) receptor trk-a, trk-b and/or trk-c.. .
Merck Sharp & Dohme Corp.


Bone tissue engineering by ex vivo stem cells ongrowth into three-dimensional trabecular metal


Adult autologous stem cells cultured on a porous, three-dimensional tissue scaffold-implant for bone regeneration by the use of a hyaluronan and/or dexamethasone to accelerate bone healing alone or in combination with recombinant growth factors or transfected osteogenic genes. The scaffold-implant may be machined into a custom-shaped three-dimensional cell culture system for support of cell growth, reservoir for peptides, recombinant growth factors, cytokines and antineoplastic drugs in the presence of a hyaluronan and/or dexamethasone alone or in combination with growth factors or transfected osteogenic genes, to be assembled ex vivo in a tissue incubator for implantation into bone tissue..

Stabilised solid compositions of factor vii polypeptides


The invention relates to chemically as well as physically stable compositions comprising factor vii or a factor vii-related polypeptide such that these compositions can be stored, handled and used at room temperature.. .
Novo Nordisk Healthcare Ag


High osteocalcin microcrystalline hydroxyapatite for calcium supplement


An improved manufacturing process produces microcrystalline hydroxyapatrte with sustained gradual calcium release that avoids spiking in blood calcium levels. Although the improved material did not cause significant elevation of blood calcium, it was just as effective in promoting bone mineralization as conventional calcium supplements.
Waitaki Biosciences


Cartilage product


The present invention relates to a method for preparing a cartilage product comprising a protein hydrolysate with a degree of hydrolysis comprised between 0.5% and 3.0%, at least one glycosaminoglycan and at least one growth factor. The present invention also relates to the cartilage product obtainable through said method.
Bioiberica, S.a.


Targeting the egfr-sglt1 interaction for cancer therapy


A compound can destabilize an epidermal growth factor receptor (egfr) protein and a sodium/glucose co-transporter 1 (sglt 1) protein. In one embodiment, the compound is a peptide derived from the interacting domain of egfr.
The University Of Houston System


Methods and compositions for the prevention or treatment of barth syndrome


The disclosure provides methods of preventing or treating barth syndrome in a mammalian subject, reducing risk factors associated with barth syndrome, and/or reducing the likelihood or severity of barth syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to increase expression of taz1 in subjects in need thereof..
Stealth Biotherapeutics Corp.


Therapeutic method using cardiac tissue-derived pluripotent stem cells


An object of the present invention is to provide a stem cell applicable to regenerative therapeutic method, and to provide a technique to carry out regenerative therapy using the cell. A collected cardiac tissue fragment is enzymatically treated to prepare a cell suspension.
Kyoto University


Freeze-dried formulations of fgf-18


The invention relates to the field of pharmaceutical formulations. More particularly it is directed to freeze-dried formulations of fibroblast growth factor 18 (fgf-18) compound and to methods of producing such formulations.
Ares Trading S.a.


Dynamic enterprise security control based on user risk factors


Aspects dynamically set enterprise-level security rules by assessing risk factors associated with a user. Risk values representing likelihoods of loss of enterprise secure data are determined for different attributes of a user, and added together to generate a user risk factor.
International Business Machines Corporation


Compressor having a control and diagnostic module


A system and method includes a power supply that generates an alternating current power for powering a compressor with a capacitor, a voltage sensor that measures voltage values based on the alternating current power, a current sensor that measures current values based on the alternating current power, and a controller. The controller communicates with the voltage sensor and the current sensor, determines a power factor value based on at least one of the voltage values and at least one of the current values, and determines a fault in the capacitor based on the power factor and at least one of the current values..
Emerson Climate Technologies, Inc.


Systems and methods for constructing programmable credential and security cards


A method for designing and constructing a thin programmable dynamic credential card is disclosed. The thin programmable dynamic credential card may comprise nine different layers carefully constructed to house a battery, a processor, a wireless communication system, a solenoid coil, a graphical display, input buttons, and other electrical components all within the thin form factor of a credit card..
Qvivr, Inc.


Cover attachment with flexible display


A tablet device with a flexible cover is disclosed. Thin flexible display technology can be integrated into the flexible cover without affecting the overall form factor of the cover or tablet device.
Apple Inc.


Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii


Various bispecific antibodies that specifically bind to both blood coagulation factor ix/activated blood coagulation factor ix and blood coagulation factor x and functionally substitute for the cofactor function of blood coagulation factor viii, that is, the function to promote activation of blood coagulation factor x by activated blood coagulation factor ix, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor viii were successfully discovered..
Chugai Seiyaku Kabushiki Kaisha


Conjugated factor viii molecules


The present invention relates to b-domain truncated factor viii molecules with a modified circulatory half-life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules..
Novo Nordisk A/s


Compositions and methods for modulating thrombin generation


factor v peptides and methods of use thereof are disclosed.. .
The Children's Hospital Of Philadelphia


Substituted pyrazoles as heat shock transcription factor activators


The present invention relates to hsf activating compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both r and s enantiomeric forms and racemic mixtures thereof), and pharmaceutical formulations thereof. In particular, the present invention provides compounds capable of facilitating hsf1 homotrimerization, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with irregular hsf1 activity..
Chaperone Therapeutics, Inc


Portable induction electrospraying apparatus and method


Low form factor mobile electrostatic spray units and methods of using same are disclosed.. .

Biologically active implants


This invention relates to an implant for treating pathological changes in the spinal column and/or locomotor system. According to one embodiment of the invention, the implant has a surface, a body, and an enamel-like or varnish-like coating that is up to 100 μm thick, comprises a biodegradable polymer such as polylactide which has a mean molecular weight of 100 kda or less, forms an adhesive bond to the surface of the body such that when the implant is implanted, mechanical friction will not abrade or damage the coating, and is adapted to contact bone when implanted.
Depuy Synthes Products, Inc.


Method of treating haemophilia by inducing tolerance to blood factors


The present invention relates to the treatment of haemophilia. More specifically, the invention relates to a new method of inducing an immune tolerance against at least one blood factor used to treat haemophilia through the epicutaneous route by application of a skin patch device comprising a blood factor in order to continue haemophilia treatment.
Inserm (institut National De La Sante Et De La Recherche Medicale)


Methods and compositions for treating bone diseases


The invention provides methods and compositions for stimulating or promoting bone generation and regeneration, for stimulating or increasing differentiation, activation or function of osteoblasts, for inhibiting or decreasing differentiation, activation or function of osteoclasts, and for treating bone diseases such as osteonecrosis by administering to a subject a therapeutically effective amount of a pro-nerve growth factor (prongf) or a pro-brain derived neurotrophic factor (probdnf) or an analog, homolog, fragment or derivative thereof. The pro-nerve growth factor (prongf) or a pro-brain derived neurotrophic factor (probdnf) or an analog, homolog, fragment or derivative thereof may be a mutated or poorly hydrolyzed form of prongf or probdnf..
Cornell University


Detecting olfactory malingering


A test subject's answers to a forced-choice odorant test are received. The subject's answers are scored, based at least in part on identifying each of the subject's answers as correct or incorrect.

Small form-factor pluggable connector with a locking and unlocking mechanism


A small form factor pluggable connector with a locking and unlocking mechanism is disclosed. The locking and unlocking mechanism includes a torsion spring mounted on a base, an actuator rotatably mounted on a cover, a rotating member rotatably mounted on the cover and the base, and a fastening shaft inserting into a cylindrical spring body of the torsion spring and shaft holes of the cover and the base.
Teralux Technology Co., Ltd.


Semiconductor package with embedded components and making the same


A semiconductor package may include a lower substrate with one or more electronic components attached to a surface thereof and an upper substrate with one or more cavities wherein the upper substrate is attached to the lower substrate at a plurality of connection points with the one or more electronic components fitting within a single cavity or a separate cavity for each component that allow the overall form factor of the semiconductor package to remain smaller. The plurality of connection points provide a mechanical and electrical connection between the upper and lower substrate and may include solder joints there between as well as conductive filler particles that create an adhesive reinforcement matrix when compressed for assembly..
Qualcomm Incorporated


Arrangement for changing the focus of a microscope objective


Wherein x is the form factor, c1 is the curvature of the surface oriented in the direction of the object plane, and c2 is the curvature of the surface oriented in the direction of the image plane, of the axially movable lens or lens group, x lying within a range from −8<x<−1.. .





Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Factor for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Factor with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.6028

4953

1 - 1 - 101